Manuscripts and Publications

Filters: Author is Tashkin, Donald P  [Clear All Filters]
2022
Fortis S, Quibrera PM, Comellas AP, Bhatt SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, R Barr G, Arjomandi M et al..  2022.  Bronchodilator Responsiveness in Tobacco-Exposed Persons with or without COPD. Chest.
W LeMaster B, P Quibrera M, Couper D, Tashkin DP, Bleecker ER, Doerschuk CM, Ortega VE, Cooper C, Han MK, Woodruff PG et al..  2022.  Clinical implications of low absolute blood eosinophil count in the SPIROMICS COPD cohort. Chest.
Barjaktarevic I, Cooper CB, Shing T, Buhr RG, Hoffman EA, Woodruff PG, M Drummond B, Kanner RE, Han MK, Hansel NN et al..  2022.  Effect of marijuana smoking on lung function change in older ever tobacco smokers.. Eur Respir J. 60(3)
Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG et al..  2022.  Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort.. Chronic Obstr Pulm Dis. 9(2):111-121.
Buhr RG, Barjaktarevic IZ, P Quibrera M, Bateman LA, Bleecker ER, Couper DJ, Curtis JL, Dolezal BA, Han MK, Hansel NN et al..  2022.  Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.. Am J Respir Crit Care Med. 206(5):554-562.
Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK et al..  2022.  Significance of FEV/FEV in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.. Chest. 161(4):949-959.
2019
Barjaktarevic IZ, Buhr RG, Wang X, Hu S, Couper D, Anderson W, Kanner RE, Iii RPaine, Bhatt SP, Bhakta NR et al..  2019.  Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.. Int J Chron Obstruct Pulmon Dis. 14:2927-2938.
2018
Pirozzi CS, Gu T, Quibrera PM, Carretta EE, Han MK, Murray S, Cooper CB, Tashkin DP, Kleerup EC, Barjaktarevic I et al..  2018.  Heterogeneous burden of lung disease in smokers with borderline airflow obstruction.. Respir Res. 19(1):223.
Morris MA, Jacobson SR, Kinney GL, Tashkin DP, Woodruff PG, Hoffman EA, Kanner RE, Cooper CB, M Drummond B, R Barr G et al..  2018.  Marijuana Use Associations with Pulmonary Symptoms and Function in Tobacco Smokers Enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Chronic Obstr Pulm Dis. 5(1):46-56.
2017
Han MK, Quibrera PM, Carretta EE, R Barr G, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL et al..  2017.  Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(8):619-626.
Martinez CH, Murray S, R Barr G, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ et al..  2017.  Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.. Ann Am Thorac Soc. 14(5):636-642.
2016
Woodruff PG, R Barr G, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE et al..  2016.  Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.. N Engl J Med. 374(19):1811-21.
Putcha N, R Barr G, Han MK, Woodruff PG, Bleecker ER, Kanner RE, Martinez FJ, Smith BM, Tashkin DP, Bowler RP et al..  2016.  Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort.. Thorax. 71:411-420.
2015
Paulin LM, Diette GB, Blanc PD, Putcha N, Eisner MD, Kanner RE, Belli AJ, Christenson S, Tashkin DP, Han ML et al..  2015.  Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease.. Am J Respir Crit Care Med. 191(5):557-65.